What Happens If You Inject Insulin Into a Vein?

Injecting insulin directly into a vein produces an extremely rapid and potentially life-threatening drop in blood sugar. In a controlled study comparing routes of administration, intravenous insulin drove plasma glucose from a normal fasting level down to about 1.45 mmol/L (roughly 26 mg/dL) within just 25 minutes, a level low enough to cause seizures, loss of consciousness, or death if untreated. That speed is the core of both the danger and, paradoxically, the reason hospitals use intravenous insulin deliberately in certain emergencies.

How Quickly Intravenous Insulin Works

When you inject insulin under the skin the usual way, it has to diffuse through tissue, enter tiny capillaries, and gradually reach the bloodstream. That process takes anywhere from 15 minutes to over an hour depending on the insulin type. Intravenous injection skips all of that. In a study comparing subcutaneous, intramuscular, and intravenous delivery of human insulin, the IV route produced a peak plasma insulin concentration at just 2 minutes after injection.¹ Two minutes. The hormone floods your entire circulation almost instantly.

The blood sugar response was equally dramatic. Plasma glucose plummeted from about 4.5 mmol/L (a normal fasting value) to 1.45 mmol/L by 25 minutes, then gradually climbed back to baseline over roughly three and a half hours.¹ That pattern matters: the crash is sudden and deep, but also relatively short-lived compared to the more gradual and sustained effect of subcutaneous injection. The problem is that “short-lived” still means hours, and the trough is dangerously low.

Why the Blood Sugar Drop Is So Steep

Insulin works by signaling cells throughout the body to pull glucose out of the blood. In muscle and fat tissue, it triggers a cascade that moves glucose transporter proteins to the cell surface, essentially opening doors for sugar to flow inside.² At the same time, insulin tells the liver to stop releasing stored glucose. The liver normally acts as a glucose reservoir, breaking down glycogen and manufacturing new glucose to keep blood levels stable between meals. Insulin suppresses both of those processes.³

When insulin arrives subcutaneously, these effects ramp up over tens of minutes and reach a moderate peak. When the same dose floods the bloodstream all at once via a vein, every insulin-sensitive tissue in the body gets the signal simultaneously and at a much higher concentration. Muscle gobbles glucose, fat gobbles glucose, and the liver slams the brakes on its own glucose output, all within minutes. Blood sugar collapses.

The Body’s Emergency Response to the Crash

Your body does not just passively watch blood sugar fall. Once glucose drops below a critical threshold, counter-regulatory hormones kick in. A study of insulin-induced hypoglycemia found that epinephrine (adrenaline), norepinephrine, growth hormone, and cortisol all surge during the crash.⁴ This is essentially a stress response. Your heart rate climbs, you start sweating, your hands may tremble, and you feel a wave of anxiety or confusion. These hormones tell the liver to dump whatever glucose it can and tell fat cells to release fatty acids as backup fuel.

In a healthy person with functioning glucagon and adrenaline responses, this counter-regulatory surge can eventually pull blood sugar back up. But in people with type 1 diabetes, the glucagon response is often blunted, meaning they lose one of their most important recovery tools.⁴ And if the intravenous insulin dose is large enough, even a fully intact counter-regulatory system can be overwhelmed. At a blood glucose of 1.45 mmol/L, the brain is not getting the fuel it needs. Confusion gives way to seizures, seizures to coma, and without treatment, death.

The Potassium Shift You Don’t See Coming

Blood sugar gets all the attention, but there is a second dangerous effect of intravenous insulin that is less obvious: it drives potassium out of the bloodstream and into cells. Insulin activates a pump on cell membranes that pushes sodium out and potassium in. The result is a dose-dependent decline in serum potassium.⁵ Ten units of IV insulin paired with dextrose reliably lowers serum potassium by about 1 mmol/L within 10 to 20 minutes, and the effect lasts four to six hours.⁵

Your heart relies on a precise balance of potassium inside and outside cells to maintain its rhythm. If serum potassium drops too fast or too far, you get hypokalemia, which can cause dangerous cardiac arrhythmias. Someone who injects insulin into a vein outside a medical setting would have no way to monitor their potassium, no IV dextrose running to prevent the blood sugar crash, and no electrolyte replacement on hand. The combination of severe hypoglycemia and falling potassium makes unsupervised IV insulin exceptionally risky.

When Hospitals Use IV Insulin on Purpose

Given all of the above, it might seem strange that hospitals deliberately put insulin into veins every day. They do, but under tightly controlled conditions and for specific reasons.

Emergency Hyperkalemia

The same potassium-lowering effect that makes unsupervised IV insulin dangerous makes it a first-line treatment when potassium is too high. Dangerously elevated potassium can stop the heart, so emergency departments use IV insulin to push potassium back into cells fast. A systematic review of the practice confirmed that 10 units of short-acting insulin given intravenously is the standard dose, with 20 units infused over an hour reserved for severe cases where potassium exceeds 6.5 mmol/L or the heart’s electrical rhythm is already distorted.⁶ Glucose is always given alongside the insulin to prevent hypoglycemia, and blood sugar is monitored frequently. Even in this supervised setting, hypoglycemia remains a recognized complication.⁶

Diabetic Ketoacidosis and Critical Care

In diabetic ketoacidosis (DKA) and other critical-care scenarios, continuous IV insulin drips allow doctors to bring blood sugar down in a controlled, titrated way. The advantage of IV over subcutaneous insulin in these situations is precision: because the effect is almost instant, clinicians can adjust the dose minute by minute. They can also stop the drip and see the insulin effect fade quickly, which matters when blood sugar is a moving target. Pediatric DKA protocols sometimes use lower insulin infusion rates than adult protocols; a systematic review comparing low-dose and standard-dose infusions in children found uncertain differences in rare complications like cerebral edema, leaving room for ongoing debate about the best approach.⁷

Measuring Insulin Sensitivity in Research

Researchers use a technique called the hyperinsulinemic-euglycemic clamp, widely considered the gold standard for measuring how sensitive the body is to insulin.⁸ The idea is straightforward: pump insulin into a vein at a constant rate to create a high, steady insulin level, then infuse glucose at whatever rate it takes to keep blood sugar normal.⁹ The more glucose you have to infuse, the more sensitive the person’s tissues are to insulin. It is a clever use of the exact pharmacology that makes IV insulin dangerous outside a lab, turned into a measurement tool under rigorous supervision.¹⁰

What Happens If You Give Long-Acting Insulin Intravenously

Most people with diabetes who use insulin have both a rapid-acting type and a long-acting type like glargine or detemir. Long-acting insulins are designed to be absorbed slowly from a subcutaneous depot, giving a flat, prolonged effect over 18 to 24 hours. A reasonable question is whether those long-acting properties survive if the insulin goes straight into a vein instead.

They do not. A study comparing intravenous glargine to intravenous regular insulin found that their effects on glucose output and tissue glucose uptake were essentially identical when given by vein.¹¹ The long-acting behavior of glargine comes entirely from its slow absorption out of the subcutaneous tissue, not from any difference in what it does once it reaches the blood. Inject it into a vein and it acts fast, just like regular insulin. This is why hospitals only use rapid- or short-acting insulin in IV protocols, and why accidentally giving a long-acting insulin IV would produce the same acute danger as giving regular insulin IV.

Effects on Blood Vessels and the Heart

Beyond glucose and potassium, intravenous insulin has direct effects on your blood vessels. Insulin stimulates the lining of blood vessels to produce nitric oxide, a molecule that relaxes vessel walls and causes vasodilation.¹² This increases blood flow to skeletal muscle, which in turn helps muscle take up more glucose. Research in humans confirmed that insulin’s ability to widen blood vessels is mediated through this nitric oxide pathway and plays a role in regulating arterial pressure when insulin levels are elevated.¹³

The heart itself changes its fuel source in response to IV insulin. Under normal fasting conditions, the heart runs primarily on fatty acids. When researchers clamped insulin levels at about seven times fasting values while keeping blood sugar normal, the heart’s uptake of glucose, lactate, and pyruvate all increased substantially, while its extraction of fatty acids, glycerol, and ketone bodies essentially stopped. The heart switched from burning fat to burning carbohydrate, and it did so without any change in heart rate, blood flow, or oxygen consumption.¹⁴ The organ kept doing the same amount of work, it just changed its fuel. This is a routine metabolic shift that happens every time you eat a meal and insulin rises, but IV delivery makes it happen faster and more completely.

A Practical Problem in Hospitals: Insulin Sticking to Tubing

Even in clinical settings where IV insulin is given intentionally, there is a quirk that complicates dosing. Insulin sticks to the inside of plastic IV tubing. This adsorption decreases the concentration of the insulin solution that actually reaches the patient, especially during the first minutes of an infusion when the tubing interior is fresh and unsaturated.¹⁵ Nurses often “prime” the tubing by running insulin solution through it before connecting the line to the patient, allowing the plastic to absorb what it will so that subsequent delivery is more predictable. It is one of those small details that matters a great deal when you are trying to control blood sugar in an ICU patient and every unit counts.

Fatal Insulin Overdoses and Forensic Complexity

The extreme potency of intravenous insulin has made it a method of both suicide and, rarely, homicide. A review of fatal insulin overdose cases found wildly elevated insulin levels in postmortem blood, with values ranging from 1 to 3,200 mU/L and an average around 594 mU/L, far beyond the normal fasting range of roughly 2 to 25 mU/L.¹⁶ Some cases involved IV lines still in the arm at the time of discovery.

Forensic investigation of suspected insulin deaths is notoriously difficult. Insulin levels degrade quickly after death, and distinguishing exogenous insulin (injected from outside) from endogenous insulin (made by the body) requires measuring C-peptide, a byproduct of natural insulin production. A high insulin-to-C-peptide ratio points toward exogenous administration. In the reviewed fatal cases, the average ratio was roughly 6 to 1.¹⁶ But interpreting these ratios is complicated by factors like how long after death the sample was collected, whether the person had diabetes, and what type of insulin was used. Synthetic analogs like lispro or glargine are not always detected by standard insulin assays, adding another layer of forensic difficulty.

Why Route of Administration Changes Everything

One of the clearest lessons from the research is that insulin’s behavior depends almost entirely on how it gets into your bloodstream, not on which type of insulin it is. As the glargine study showed, the differences between “fast-acting” and “long-acting” formulations disappear completely when both are given IV, because those labels describe how each formulation is absorbed from under the skin, not what insulin does once it reaches the blood.¹¹ The entire architecture of modern insulin therapy, from basal-bolus regimens to insulin pumps, is built on manipulating absorption speed. Bypass that layer and you get the same molecule doing the same things, just doing them all at once.

This is also why accidental IV injection is so dangerous. A dose calibrated for subcutaneous delivery, designed to trickle into the blood over hours, instead arrives as a bolus. The body encounters in seconds what it was supposed to receive over a long stretch. Even a routine dose of long-acting insulin could produce severe hypoglycemia and hypokalemia if it accidentally entered a vein, because the safety margin built into subcutaneous dosing vanishes entirely. Hospitals mitigate this with glucose co-infusions, continuous monitoring, and electrolyte checks. Outside that environment, the margin for error is effectively zero.

1
The Lancet. Comparative Study of Subcutaneous, Intramuscular, and Intravenous Administration of Human Insulin
2
PubMed Central. Insulin signalling and GLUT4 trafficking in insulin resistance
3
PubMed Central. Insulin regulation of gluconeogenesis
4
Diabetes. Important role of adrenergic mechanisms in acute glucose counterregulation following insulin-induced hypoglycemia in type I diabetes
5
Oxford Academic. Insulin for the treatment of hyperkalemia: a double-edged sword?
6
PLOS ONE. Optimal Dose and Method of Administration of Intravenous Insulin in the Management of Emergency Hyperkalemia: A Systematic Review
7
PubMed Central. Insulin Infusion Dosing in Pediatric Diabetic Ketoacidosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
8
PubMed Central. Hyperinsulinemic-euglycemic clamps in conscious, unrestrained mice
9
PubMed. Glucose clamp technique: a method for quantifying insulin secretion and resistance
10
PubMed. Hyperinsulinemic-euglycemic clamp to assess insulin sensitivity in vivo
11
Diabetes Care. Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation/deactivation kinetic profiles
12
Current Diabetes Reports. Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium
13
JCI Insight. Nitric oxide release accounts for insulin’s vascular effects in humans
14
American Journal of Physiology-Endocrinology and Metabolism. Metabolic and hemodynamic effects of insulin on human hearts
15
PubMed Central. The Effect of Tubing Dwell Time on Insulin Adsorption During Intravenous Insulin Infusions
16
SpringerOpen. Characteristics of fatal insulin overdoses